FDA Panel Recommends Against De Novo Classification For Genetic OUD Risk Test
Executive Summary
The FDA Clinical Chemistry and Toxicology Devices Panel voted 11-2 that the risks of AvertD’s genetic test for opioid use disorder outweigh the product’s potential benefits as a diagnostic.